Business
AstraZeneca chief quits CSL board over $50 billion acquisition – Sydney Morning Herald
AstraZeneca’s Pascal Soriot will depart the CSL board next month to prevent potential conflicts of interest after his company bought a US immunology startup.
AstraZeneca announced its planned acquisition of Alexion for $US39 billion ($50.4 billion) in the second week of December, with Mr Soriot telling his investors the deal would allows us to enhance our presence in immunology.
Based in Boston, Alexion develops treatments for rare diseases including in the blood and heart conditions, where CSL is a major player.
CSL, which is producing doses of AstraZenecas COVID-19 vaccine in Australia, told investors last year that Mr Soriots appointment did not look…
-
Noosa News16 hours agoTallest tower outside CBD approved for construction at 205 metres
-
Noosa News21 hours agoTrucking company penalised for refusing to pay unfairly sacked worker
-
General23 hours agoVacherot becomes lowest-ranked ATP Masters winner after defeating his cousin Rinderknech in Shanghai
-
Noosa News17 hours agoFarmgate Backpackers leads with integrity amid industry challenges